Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07744919 Emapalumab-LZSG Hepatic Encephalopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07744919 clinical trial report covering Emapalumab-LZSG, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07743632 Cyclophosphamide Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07743632 clinical trial report covering Cyclophosphamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07744126 Telisotuzumab adizutecan Squamous cell carcinoma of head and neck metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07744126 clinical trial report covering Telisotuzumab adizutecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07743554 Avutometinib Neurofibrosarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07743554 clinical trial report covering Avutometinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07725562 VG081821AC Young onset Parkinson disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07725562 clinical trial report covering VG081821AC, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07734792 Tirzepatide Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734792 clinical trial report covering Tirzepatide, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07742280 Brexpiprazole Schizophrenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07742280 clinical trial report covering Brexpiprazole, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07736495 Lipoic acid Chemotherapy oral mucositis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07736495 clinical trial report covering Lipoic acid, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07739199 PD-1/VEGF Trispecific Antibody(Harbour) Squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07739199 clinical trial report covering PD-1/VEGF Trispecific Antibody(Harbour), Phase 2/3, endpoints, sponsor, geography, readout timing and developmen
Latest Hotspot
8 min read
NCT07739186 PD-1/VEGF Trispecific Antibody(Harbour) Metastatic Non-Squamous Non-Small Cell Lung Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07739186 clinical trial report covering PD-1/VEGF Trispecific Antibody(Harbour), Phase 2/3, endpoints, sponsor, geography, readout timing and developmen
Latest Hotspot
8 min read
NCT07742553 Finasteride Hypogonadism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07742553 clinical trial report covering Finasteride, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07725484 Lipoic acid Coronary Artery Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07725484 clinical trial report covering Lipoic acid, Phase 3, endpoints, sponsor, geography, readout timing and development white space.